Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Oncologist|June 29, 2026
Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid TumorsApostolia Maria Tsimberidou, Darren Sigal, Anna Varghese, et al.
Nature Communications|January 23, 2020
Non-invasive characterization of human bone marrow stimulation and reconstitution by cell-free messenger RNA sequencingArkaitz Ibarra, Jiali Zhuang, Yue Zhao, et al.
Immunity|December 16, 2018
Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing ImmunosurveillanceYuki Nakanishi, Angeles Duran, Antoine L'Hermitte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic CancerMitesh J Borad, Shantan G Reddy, Nathan Bahary, et al.
The Journal of Molecular Diagnostics : JMD|March 1, 2025
Detection of Gene Fusions and Rearrangements in Formalin-Fixed, Paraffin-Embedded Solid Tumor Specimens Using High-Throughput Chromosome Conformation CaptureKristyn Galbraith, Jamin Wu, Kristin Sikkink, et al.
Cancer Cell|December 16, 2022
Hyaluronan driven by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal cancerAnxo Martinez-Ordoñez, Angeles Duran, Marc Ruiz-Martinez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic AdenocarcinomaEric Van Cutsem, Margaret A Tempero, Darren Sigal, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
Pageof 2